Evidence map›Paper›PMID 39022684›Full record

ReviewNon-coding RNA research2024

Interplay between JAK/STAT pathway and non-coding RNAs in different cancers.

Ammad Ahmad Farooqi, Abay M Shepetov, Venera Rakhmetova, Zharilkassimov Ruslan, Aigul Almabayeva, Saniya Saussakova, Kaini Baigonova, Kainish Baimaganbetova, Kalmakhanov Sundetgali, Gulnara Kapanova

Abstract readReview
In one paragraph

Review in Non-coding RNA research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ammad Ahmad FarooqiDepartment of Molecular Oncology, Institute of Biomedical and Genetic Engineering (IBGE), Islamabad, Pakistan.
Abay M ShepetovDepartment of Nephrology, Asfendiyarov Kazakh National Medical University, Tole Bi St 94, Almaty, 050000, Kazakhstan.
Venera RakhmetovaMedical University of Astana, Astana, 010000, Kazakhstan.
Zharilkassimov RuslanDepartment of Surgical Diseases with a Course of Cardio-thoracic Surgery and Maxillofacial Surgery, NJSC "Astana Medical University", Astana, Kazakhstan.
Aigul AlmabayevaDepartment of Human Anatomy, NJSC "Astana Medical University", Astana City, Kazakhstan.
Saniya SaussakovaDepartment of Public Health and Management, NJSC "Astana Medical University", Astana, Kazakhstan.
Kaini BaigonovaAl-Farabi Kazakh National University, Kazakhstan.
Kainish BaimaganbetovaAl-Farabi Kazakh National University, Kazakhstan.
Kalmakhanov SundetgaliAl-Farabi Kazakh National University, Kazakhstan.
Gulnara KapanovaAl-Farabi Kazakh National University, Kazakhstan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Progress in the identification of core multi-protein modules within JAK/STAT pathway has enabled researchers to develop a better understanding of the linchpin role of deregulated signaling cascade in carcinogenesis and metastasis. More excitingly, complex interplay between JAK/STAT pathway and non-coding RNAs has been shown to reprogramme the outcome of signaling cascade and modulate immunological responses within tumor microenvironment. Wealth of information has comprehensively illustrated that most of this complexity regulates the re-shaping of the immunological responses. Increasingly sophisticated mechanistic insights have illuminated fundamental role of STAT-signaling in polarization of macrophages to M2 phenotype that promotes disease aggressiveness. Overall, JAK/STAT signaling drives different stages of cancer ranging from cancer metastasis to the reshaping of the tumor microenvironment. JAK/STAT signaling has also been found to play role in the regulation of infiltration and activity of natural killer cells and CD4/CD8 cells by PD-L1/PD-1 signaling. In this review, we have attempted to set spotlight on regulation of JAK/STAT pathway by microRNAs, long non-coding RNAs and circular RNAs in primary tumors and metastasizing tumors. Therefore, existing knowledge gaps need to be addressed to propel this fledgling field of research to the forefront and bring lncRNAs and circRNAs to the frontline of clinical practice. Leveraging the growing momentum will enable interdisciplinary researchers to gain transition from segmented view to a fairly detailed conceptual continuum.

Identifiers

PMID39022684
PMCPMC11254501

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.